Compare DLPN & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | AYTU |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8M | 20.5M |
| IPO Year | N/A | N/A |
| Metric | DLPN | AYTU |
|---|---|---|
| Price | $1.65 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.17 |
| AVG Volume (30 Days) | 34.5K | ★ 56.3K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $53,371,115.00 | ★ $63,696,000.00 |
| Revenue This Year | $9.05 | N/A |
| Revenue Next Year | $15.42 | $29.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.86 | N/A |
| 52 Week Low | $0.75 | $0.95 |
| 52 Week High | $1.88 | $2.82 |
| Indicator | DLPN | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 46.36 |
| Support Level | $1.60 | $1.91 |
| Resistance Level | $1.84 | $2.18 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 31.58 | 39.24 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.